In this article, we have summarized novel targets for NB, such as ISL1 (Zhang et al., 2018; Zhang et al., 2019; Li et al., 2021), DPYSL3 (Cheung et al., 2008; Chicco et al., 2023), and ROR1 (Janovská and Bryja, 2017; Quezada and Lopez-Bergami, 2023), along with immunotherapy which is an emerging and promising treatment approach for this disease. Here, DPYSL3 is linked to neuroblastoma.